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ABSTRACT:
Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer, 
and often derives from pre-existing well-differentiated tumors. Despite a relatively 
low prevalence, it accounts for a disproportionate number of thyroid cancer-related 
deaths, due to its resistance to any therapeutic approach. Here we describe the first 
mouse model of ATC, obtained by combining in the mouse thyroid follicular cells 
two molecular hallmarks of human ATC: activation of PI3K (via Pten deletion) and 
inactivation of p53. By 9 months of age, over 75% of the compound mutant mice 
develop aggressive, undifferentiated thyroid tumors that evolve from pre-existing 
follicular hyperplasia and carcinoma. These tumors display all the features of their 
human  counterpart,  including  pleomorphism,  epithelial-mesenchymal  transition, 
aneuploidy, local invasion, and distant metastases. Expression profiling of the murine 
ATCs  reveals  a  significant  overlap  with  genes  found  deregulated  in  human  ATC, 
including genes involved in mitosis control. Furthermore, similar to the human tumors, 
[Pten, p53]thyr-/- tumors and cells are highly glycolytic and remarkably sensitive to 
glycolysis inhibitors, which synergize with standard chemotherapy. Taken together, 
our results show that combined PI3K activation and p53 loss faithfully reproduce 
the  development  of  thyroid  anaplastic  carcinomas,  and  provide  a  compelling 
rationale for targeting glycolysis to increase chemotherapy response in ATC patients.
INTRODUCTION
Thyroid cancer is the most common endocrine 
neoplasm, and one of the few tumor types for which 
incidence has been increasing over the past 20 years 
[1]. Well-differentiated thyroid cancers (papillary and 
follicular) have generally a good prognosis and can be 
effectively managed through a combination of surgery 
and radioactive iodine treatment [2]. Anaplastic thyroid 
carcinoma (ATC) represents the most aggressive and 
undifferentiated subtype of thyroid cancer. It often 
coexists with well-differentiated tumors, suggesting that 
it arises from pre-existing follicular or papillary tumors 
[3, 4]. Although it comprises less than 5% of thyroid 
malignancies, ATC accounts for up to 40% of deaths 
from thyroid cancer [5]. In fact, ATC is almost invariably 
lethal, with no effective therapy available [6, 7]. Thus, 
its median survival of around 4 months, due to rapid 
onset, tracheal and esophageal invasion, and uncontrolled 
metastases to the lungs and, to a less extent, to bones, skin 
and brain, has not changed in more than half a century 
[8]. Dedifferentiation, a hallmark of ATC, is manifested Oncotarget 2011; 2:  1109 - 1126 1110 www.impactjournals.com/oncotarget
by  loss  of  specific  thyroid  cell  characteristics  and 
functions, including expression of thyroglobulin, thyroid 
peroxidase, thyroid stimulating hormone receptor and 
the Na/I symporter, NIS [9]. Other ATC characteristics 
include pleomorphism, with often coexisting areas of 
squamoid, spindle cell, and giant cell morphology [10], 
epithelial-to-mesenchymal transition [7], and neutrophilic 
infiltrate [11].
Molecular characterization of ATCs has revealed a 
high degree of chromosomal instability and aneuploidy 
[12]. In addition, common alterations in a number of 
signal  transduction  pathways  have  been  identified. 
Molecular changes that characterize ATC have been 
recently reviewed in a number of publications [9, 13, 
14], and involve most often p53 loss or inactivation, and 
activation of the PI3K cascade, of RAS family members, 
or of BRAF.
One major obstacle to the development of more 
effective therapeutic approaches to ATC has been the lack 
of an immunocompetent, autochthonous mouse model 
closely recapitulating the clinicopathological features 
of  human  ATC.  In  spite  of  significant  advancements, 
most genetically engineered mouse models described to 
date only develop differentiated thyroid cancer, such as 
PTC [15-17] and FTC [18-20]. One notable exception 
is represented by the BrafV600E transgenic model, which 
develops poorly differentiated foci from concurrent 
papillary lesions [21]
In this study, we report the characterization of the 
first  mouse  model  of ATC,  based  on  the  simultaneous 
activation of the PI3K signaling cascade and inactivation 
of p53 in the mouse thyroid epithelial cells. The tumors 
developing in these mice closely phenocopy human ATCs, 
Figure 1: Clinicopathological features of [Pten, p53]thyr-/- mice. (A) Kaplan-Meyer analysis of the effect of progressive p53 
deletion on the survival of Ptenthyr-/- mice. (B, C) TSH and T4 serum levels in control, single mutant and double mutant (DM) mice. 
(D-K) Histopatological features of tumors developing in [Pten, p53]thyr-/- mice. (D) Anaplastic carcinoma (left) flanking an area of well-
differentiated follicular carcinoma (right). Undifferentiated tumors display areas of spindle cell morphology (E), with frequent giant cells 
(F), and occasional bone metaplasia (G). Tumors invade locally into the muscle (H), and the trachea (I), and metastasize to the lungs (J) or, 
sporadically, to the liver (K). Bar: 100µm.Oncotarget 2011; 2:  1109 - 1126 1111 www.impactjournals.com/oncotarget
undergo the glycolytic shift known as Warburg effect, and 
are highly sensitive to the therapeutic use of glycolytic 
inhibitors. Thus, this model represents a novel, powerful 
tool to understand the biology of human thyroid anaplastic 
carcinomas, and to develop innovative therapeutic 
approaches for what is today still a lethal disease.
Figure 2. Expression profiling by real-time PCR of a panel of thyroid differentiation markers using thyroid pools from 4-month old 
control and single mutant mice, ATC-free, progressively older (4, 6, 8 months) double mutants, and histologically confirmed ATCs from 
8- to 9-month old double mutants.Oncotarget 2011; 2:  1109 - 1126 1112 www.impactjournals.com/oncotarget
RESULTS
Anaplastic thyroid carcinoma development in 
[Pten, p53]thyr-/- mice
Mice with a targeted deletion of the Pten tumor 
suppressor gene in the thyroid follicular cells exhibit 
constitutive PI3K pathway activation and develop, from 
birth, hyperplastic glands that progress to nodular lesions 
by 6-10 months of age [22] and to well-differentiated 
follicular carcinomas after one year of age [19]. Building 
on available clinicopathological data that point at p53 as 
the most commonly mutated or deleted gene in anaplastic 
thyroid tumors, we crossed the Pten mutants with mice 
carrying  a  floxed  p53 allele in order to model more 
aggressive thyroid tumors. Thyroid-specific p53 loss did 
not cause any overt phenotype (Figure 1A and data not 
shown). Conversely, concomitant loss of p53 dramatically 
reduced the survival of Ptenthyr-/- mice (median survival 38.4 
weeks vs. 75.3 weeks), while reduction to heterozygosity 
of either allele, in the absence of the other, resulted in an 
intermediate phenotype (median survival: 61.3 weeks for 
[Ptenthyr-/-, p53thyr+/-] mice, and 58.45 weeks for [Ptenthyr+/-, 
p53thyr-/-] mice) (Figure 1A). Similar to Ptenthyr-/- mice, 
[Pten, p53]thyr-/- compound mutants displayed drastically 
reduced Thyroid-Stimulating Hormone (TSH) serum 
levels. However, the absence of significantly increased 
T4 hormone levels suggests that TSH suppression is not 
the consequence of relieving the physiological negative 
feedback normally induced by elevated thyroid hormone 
levels (Figure 1B, C). 
Post mortem analysis of 8-10 month old [Pten, p53]
thyr-/- mutants revealed in all cases a strikingly enlarged 
thyroid gland (average gland weight 392±350 mg, vs. 
3.7±1.1 mg in age-matched controls) causing severe 
tracheal compression and adhering to adjacent tissues. 
Histopathological analysis showed the coexistence 
of small remnants of well-differentiated follicular 
carcinomas, similar to those developing in aging Ptenthyr-/- 
mice, and of more extensive pleomorphic areas (Figure 
1D) exhibiting, as in human anaplastic carcinomas, 
spindle cell morphology (Figure 1E), giant, osteoclast-
like, multinucleated cells (Figure 1F), and even areas 
of osseous metaplasia (Figure 1G). These aggressive 
tumors invaded locally into the muscle (Figure 1H) and 
trachea (Figure 1I) and, in 28% of mice, metastasized 
to the lungs (Figure 1J) or, albeit less often, to the liver 
(Figure 1K). Conversely, analysis of thyroids from 4-8 
month old [Pten, p53]thyr-/- mice only showed areas of well 
differentiated follicular carcinomas, indistinguishable 
from those developing in older Ptenthyr-/- mice (data not 
shown). Thus, combined loss of p53 and PI3K activation 
in the thyroid follicular cells results in the development of 
aggressive, metastatic tumors closely resembling human 
thyroid anaplastic carcinomas.
Figure 3: Mouse ATCs display chromosomal instability 
and aneuploidy. (A) Chromosome counts in two representative 
early passage (p2) primary cultures from histologically confirmed 
ATCs. Note the wide distribution of chromosome numbers within 
the same culture. (B) Karyotypic analysis of two representative 
cells from independent tumors, showing chromatid breaks (thick 
arrows), chromosome breaks (thin arrows), translocations (#), 
and complex rearrangements (*).
A
B
Figure 4: [Pten, p53]thyr-/- ATCs undergo EMT. (A) H&E 
staining of a representative tumor area containing both a follicular 
carcinoma (left) and an anaplastic carcinoma (right) component. 
(B-D) Immunohistochemical detection of phospho-Smad 2 (B), 
E-cadherin (C), and vimentin (D). Bar: 100µm.Oncotarget 2011; 2:  1109 - 1126 1113 www.impactjournals.com/oncotarget
Mouse ATCs undergo dedifferentiation, genomic 
instability, and EMT
Loss of thyrocyte differentiation is a hallmark 
of human ATC. We used real time PCR to measure the 
expression levels of a panel of genes associated with 
thyroid differentiation and function in freshly dissected 
glands and tumors. Expression of the Foxe1, Pax8, and 
Nkx2-1 transcription factors, as well as of the thyroid-
specific genes Duox2, Tpo, Tg, Tshr, and Slc5a5 (Nis) was 
generally not altered in single mutants nor in [Pten, p53]
thyr-/- mice up to 8 months of age, before the development 
of frank ATC. However, expression of each of these 
markers was reduced to almost undetectable levels in 
every anaplastic tumor analyzed (Figure 2), supporting 
the notion that the tumors developing in the compound 
mutants are indeed undifferentiated carcinomas. 
A second frequent aspect of human ATC is an 
elevated degree of genomic instability, leading to marked 
aneuploidy. We analyzed metaphase spreads from 
early passage primary cultures of several histologically 
confirmed  anaplastic  carcinomas,  and  found  that 
these cells were invariably aneuploid (Figure 3A), 
with evidence of widespread chromosomal damage, 
including chromosome and chromatid breaks, complex 
rearrangements, translocations, premature centromere 
division, and the presence of chromosomal debris 
(Figure 3B). Thus, combined loss of the Pten and p53 
tumor suppressors leads to tumors that display genomic 
instability.
To further validate the [Pten, p53]thyr-/- strain as a model 
of human ATC, we performed immunohistochemistry on 
paraffin sections from 9-10 month old mice displaying 
Figure 5: ATCs are addicted to driver gene signaling. (A) Western blotting analysis of the activation status of Akt and MAPK 
pathways in 4-month old control and single mutant mice, ATC-free, progressively older (4, 6, 8 months) double mutants, and histologically 
confirmed ATCs from 8- to 9-month old double mutants. (B) immunohistochemical detection of activated Akt, S6 ribosomal protein, and 
ERK1/2 in tumor areas with both well-differentiated and anaplastic components. (C) IC50 values for an Akt inhibitor (MK-2206) and a 
MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a 
Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500nM, 
U0126: 10µM).Oncotarget 2011; 2:  1109 - 1126 1114 www.impactjournals.com/oncotarget
both well-differentiated and undifferentiated tumor 
areas in order to determine whether these tumors display 
epithelial-to-mesenchymal transition (EMT). Strikingly, 
the undifferentiated area of all the tumors analyzed had 
lost the expression of the epithelial marker E-cadherin, 
had acquired the expression of the mesenchymal marker 
Vimentin, and displayed high levels of phosphorylated 
Smad2 (Figure 4). No EMT was detected on thyroid 
sections from younger mice (not shown). These data show 
that the tumors developing in the compound mutants 
invariably undergo EMT, and strongly suggest that this 
process is, at least in part, under the control of elevated 
Tgf-β signaling. 
A large subset of human ATCs is characterized by 
activating BRAF or RAS mutations. To determine whether 
the ATCs developing in [Pten, p53]thyr-/- mice have somatic 
activating mutations in either Braf or in one of the three 
Ras genes, we sequenced the known hotspots (Braf exons 
Figure 6: Expression profiling validates the [Pten, p53]thyr-/- mouse as a clinically relevant model of human ATC. (A) 
Hierarchical clustering showing the unique expression profile of mouse ATCs when compared to controls, single mutants, ATC-free double 
mutants (DM), and follicular carcinomas developing in aging Ptenthyr-/- mice (FTC). (B) Venn’s diagram showing the significant overlap 
between genes differentially regulated in mouse and human ATCs. (C) GSEA analysis of the 430 genes common to mouse and human ATC, 
showing significant enrichment in genes previously shown to be altered in human ATC cell lines as well as genes involved in the control 
of mitosis.Oncotarget 2011; 2:  1109 - 1126 1115 www.impactjournals.com/oncotarget
11 and 15, H-; N-, and Kras exons 1 and 2) in five cell 
lines established from tumors developed by [Pten, p53]
thyr-/- double mutant mice. All cell lines had wild type 
sequences, strongly suggesting that neither Braf nor Ras 
isoforms are involved in ATC development in this mouse 
model (data not shown).
ATCs are addicted to driver gene signaling
Loss of Pten is anticipated to lead to constitutive 
phosphorylation of Akt and deregulation of its downstream 
targets. Indeed, western blot analysis of thyroid extracts 
from control, single, and young double mutants showed 
elevated pSer473-Akt, pThr389-S6k, and pSer240/244-S6 in 
thyroids lacking Pten (Figure 5A). Double mutant glands 
also displayed moderate levels of pERK1/2. ATCs were 
characterized by a somewhat increased phosphorylation 
of S6, and by variable levels of pERK1/2. However, when 
phosphorylation and activation of these proteins was 
examined by IHC, we found that Akt phosphorylation 
was higher in the remnants of well-differentiated lesions 
within the tumor than in the anaplastic component, which 
instead showed higher levels of pS6 (Figure 5B). This 
finding suggests that the well-known negative feedback 
mediated by S6k and IRS-1 [23] might be favored or 
enhanced in ATCs. Furthermore, it may underline a 
reduced dependence of fully developed ATCs on Akt 
signaling.
In the same tumors, ERK1/2 activation was restricted 
to scattered patches of cells, often near the invasive edges 
of the undifferentiated components.
The accumulating genetic alterations consequent the 
high degree of genomic instability within ATCs might alter 
the dependence of these tumors on their driver oncogenic 
alteration, i.e. increased Akt signaling. We used two cell 
lines, T1860 and T1903, which we have derived from 
anaplastic tumors developed by [Pten, p53]thyr-/- mice, to 
determine the sensitivity of these murine ATCs cells to 
Ingenuity Canonical Pathways P-value Ratio Molecules 
in pathway
Hepatic Fibrosis / Hepatic Stellate Cell Activation 0.00000 0.347 51/147
Leukocyte Extravasation Signaling 0.00000 0.276 55/199
LPS/IL-1 Mediated Inhibition of RXR Function 0.00000 0.247 54/219
PropanoateMetabolism 0.00000 0.190 23/121
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 0.00000 0.246 59/240
LXR/RXR Activation 0.00002 0.280 26/93
Valine, Leucine and Isoleucine Degradation 0.00002 0.226 24/106
Metabolism of Xenobiotics by Cytochrome P450 0.00003 0.142 28/197
Atherosclerosis Signaling 0.00003 0.271 29/107
Aryl Hydrocarbon Receptor Signaling 0.00004 0.239 38/157
Urea Cycle and Metabolism of Amino Groups 0.00005 0.179 14/78
Fatty Acid Metabolism 0.00006 0.179 33/184
Arginine and ProlineMetabolism 0.00006 0.136 24/177
Pancreatic Adenocarcinoma Signaling 0.00006 0.269 32/119
ILK Signaling 0.00007 0.238 46/193
β-alanine Metabolism 0.00012 0.194 18/93
GliomaInvasiveness Signaling 0.00012 0.333 20/60
Colorectal Cancer Metastasis Signaling 0.00019 0.218 56/257
Inhibition of Angiogenesis by TSP1 0.00019 0.359 14/39
Cell Cycle Control of Chromosomal Replication 0.00021 0.387 12/31
Bladder Cancer Signaling 0.00022 0.283 26/92
HIF1α Signaling 0.00024 0.269 29/108
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 0.00025 0.265 27/102
IL-8 Signaling 0.00026 0.223 43/193
TR/RXR Activation 0.00068 0.260 25/96
Table 1: Top 25 deregulated pathways identified in mouse ATCs, using the Ingenuity Pathways Analysis (IPA) system.Oncotarget 2011; 2:  1109 - 1126 1116 www.impactjournals.com/oncotarget
specific pathway inhibition, and compared them to the 
human follicular carcinoma line FTC-133 (PTEN and 
p53 mutant), and the human ATC lines CAL-62 (KRAS 
and p53 mutant) and C643 (HRAS and p53 mutant). One-
hour treatment with the AKT inhibitor MK-2206 (0.5µM) 
or with the MEK inhibitor U0126 (10µM) effectively 
abolished AKT and ERK1/2 phosphorylation in all cell 
lines (Figure 5C). The effect of both compounds on cell 
viability, measured by determining the IC50 after 72h 
treatment, clearly correlated with the cell lines’ genetic 
makeup, with Pten-/- cells being more sensitive to AKT 
inhibition than Pten+/+ cells, and Ras mutant cells more 
sensitive to MEK inhibition than cells with wild type Ras 
(Figure 5C).
Thus, although mouse ATCs display lower pAkt 
levels than coexisting well-differentiated tumor areas, 
they still depend on Akt signaling for their survival and 
proliferation.
MouseGene
Hs1 ATC Hs2 ATC Mm ATC
MouseGene
Hs1 ATC Hs2 ATC Mm ATC
Upregulated Downregulated
*Timp1 4.699 5.213 21.086 Patz1 0.436 0.216 0.293
*Steap1 3.760 14.778 10.021 Suox 0.729 0.297 0.291
*Itga5 2.426 4.675 8.795 Epb4.1l4b 0.107 0.029 0.286
Kif20a 2.221 22.184 7.664 Tnxb 0.581 0.264 0.285
Ccnb1 5.664 11.688 7.395 Fxyd1 0.651 0.307 0.279
Ccna2 3.119 14.546 7.167 Grb14 0.748 0.342 0.276
*Racgap1 7.247 15.876 6.938 1190002H23Rik 0.252 0.212 0.274
Rrm2 10.807 51.614 6.860 Slc5a3 0.220 0.153 0.273
*Prc1 5.295 26.946 6.491 Ww c1 0.384 0.297 0.260
*Tpx2 3.766 38.703 6.390 Mettl7a1 0.090 0.050 0.257
Kif4 3.613 19.001 5.861 Stxbp6 0.373 0.044 0.254
Cenpe 2.001 13.520 5.749 Tppp 0.681 0.102 0.251
Cep55 4.075 26.077 5.707 Acacb 0.527 0.069 0.242
Kif2c 2.029 9.175 5.374 Bspry 0.364 0.050 0.237
Ccdc109b 3.470 8.822 5.369 Rbpms 0.370 0.102 0.232
Plau 5.606 46.647 5.363 Cds1 0.516 0.057 0.217
Depdc1a 1.771 7.384 5.303 Nebl 0.112 0.019 0.210
Bub1b 3.180 20.421 5.246 Car4 0.273 0.053 0.203
Basp1 3.274 8.466 5.114 *Nkx2-1 0.147 0.016 0.200
Asf1b 1.904 4.015 4.831 Pdk2 0.646 0.474 0.188
Dtl 3.446 5.716 4.782 Bex1 0.178 0.025 0.182
Tyrobp 4.242 19.675 4.652 Sorbs2 0.094 0.013 0.181
Cdca8 1.837 6.322 4.577 Cldn3 0.125 0.027 0.180
Rcn1 3.697 2.780 4.547 Sall1 0.287 0.018 0.180
Cenpa 1.714 3.183 4.503 Prkcq 0.432 0.134 0.180
Foxm1 3.121 7.703 4.434 *Duox2 0.107 0.015 0.178
Nusap1 3.727 17.416 4.385 Rragd 0.222 0.163 0.174
Dlgap5 2.449 22.229 4.359 Smad9 0.691 0.024 0.173
Gpsm2 2.351 2.026 4.339 Fabp4 0.102 0.020 0.168
C3ar1 2.891 15.589 4.170 Pygm 0.733 0.605 0.164
Kntc1 1.534 7.468 4.146 Gpr56 0.166 0.092 0.161
Stil 1.787 6.955 4.098 Rap1gap 0.143 0.028 0.157
Ncaph 1.652 4.310 4.088 Erbb4 0.583 0.157 0.150
Zwilch 2.346 6.767 4.050 Bex4 0.323 0.148 0.149
Atad2 1.928 2.755 4.000 Glb1l2 0.462 0.270 0.148
Fabp5 7.508 4.293 3.954 Ager 0.683 0.392 0.144
Cks2 9.287 26.933 3.911 Lrp2 0.276 0.012 0.133
Tubb6 4.194 4.191 3.839 Ocln 0.650 0.174 0.124
Cdc20 5.251 35.621 3.822 Myo5c 0.181 0.046 0.112
Melk 5.470 15.689 3.765 Bcam 0.389 0.246 0.107
Ttk 3.254 22.640 3.702 Fam13a 0.304 0.124 0.094
Aurkb 1.639 2.222 3.661 Id4 0.050 0.009 0.091
Csf2rb 2.201 22.256 3.632 Fam189a2 0.170 0.015 0.083
Cdkn3 4.688 16.665 3.625 Cdh16 0.305 0.058 0.077
Ube2c 4.383 46.951 3.621 *Ppargc1a 0.362 0.055 0.069
Fcgr2b 2.191 15.069 3.561 *Pax8 0.095 0.014 0.063
Trip13 2.555 14.673 3.418 *Tg 0.011 0.001 0.061
Ncapg2 2.384 7.484 3.407 Kcnj16 0.034 0.003 0.045
Mad2l1 5.281 15.378 3.398 *Tshr 0.029 0.005 0.045
Mcm3 1.584 2.853 3.366 *Tpo 0.039 0.003 0.036
Table 1: Top 50 genes deregulated (FDR<0.1) in both mouse and human ATC, ranked by expression level in mouse.Oncotarget 2011; 2:  1109 - 1126 1117 www.impactjournals.com/oncotarget
A “mitotic gene signature” in mouse and human 
ATCs 
To gain insight into the molecular characteristics of 
ATCs developed by [Pten, p53]thyr-/- mice, we performed 
genome-wide expression profiling using the Affymetrix 
platform on thyroids from 3-month old control, single, 
and double mutant mice, as well as on five follicular and 
five  anaplastic  carcinomas  developed  by  Ptenthyr-/- and 
[Pten, p53]thyr-/- mice, respectively. 
As predicted by the inability of thyroid-specific p53 
deletion to yield an overt phenotype, a heat map including 
all probes with more than a 5-fold change across any of 
the six groups showed that p53-/- thyroids cluster together 
with those of wild type mice (Figure 6A). Similarly, 
no remarkable differences were apparent between the 
transcriptomes of Ptenthyr-/- and [Pten, p53]thyr-/- thyroids. 
On the contrary, the profile of [Pten, p53]thyr-/- ATCs (8-
10 months of age) was strikingly different from that of 
younger [Pten, p53]thyr-/- mice and also from that of well-
differentiated follicular carcinomas developed by aging 
Ptenthyr-/- mice (16-20 months). These data strongly suggest 
that the molecular events leading to the development and 
maintenance of ATC are unique to this tumor type and that 
characterization of these changes could uncover clinically 
relevant pathways and targets. 
Overall, using a stringent false discovery rate (FDR) 
of 5%, 2,960 genes were found deregulated ±2-fold in ATC 
samples, compared to wild type thyroids (1,395 up, and 
1,565 down). To identify biological processes significantly 
impacted by ATC development, we performed canonical 
pathway enrichment using Ingenuity Pathway Analysis 
(IPA). Significant enrichment was observed in pathways 
involved in metabolic remodeling of the tumors, in cell 
motility and invasiveness, in leukocyte recruitment and 
function, and in epithelial-mesenchymal transition (Table 
1). 
In order to determine to what extent the gene 
expression changes uncovered in [Pten, p53]thyr-/- ATCs 
overlap  with  those  identified  in  human  anaplastic 
carcinomas, we retrieved from the GEO and EBI 
repositories two datasets containing gene expression data 
from a total of six control thyroids and eight ATCs. Since 
these two available datasets had been generated using two 
different Affymetrix platforms [24, 25], we analyzed them 
separately. After adjusting for a false discovery rate <10% 
and for genes present in all three platforms, we identified 
430 genes that were simultaneously deregulated in all 
three datasets (Figure 6B and Table 2). An additional 1321 
Figure 7: Real-time PCR validation of a panel of genes differentially regulated in both mouse and human ATCs in 
4-month old control and single mutant mice, ATC-free, progressively older (4, 6, 8 months) double mutants, and 
histologically confirmed ATCs from 8- to 9-month old double mutants.Oncotarget 2011; 2:  1109 - 1126 1118 www.impactjournals.com/oncotarget
genes were co-deregulated in mouse ATCs and in at least 
one human dataset. 
Strikingly, 24 of the top 50 common up-regulated 
genes encode for proteins involved in the control of 
the G2/M transition and of the mitotic process (Table 
2, bold), indicating that mitotic deregulation is a key 
process in the development of ATC, and thus identifying 
putative clinically valuable targets. As expected, the list of 
common down-regulated genes contains several thyroid 
differentiation markers (Table 2, underlined), underlining 
the dramatic loss of differentiation that characterizes the 
development of anaplastic thyroid tumors. 
To further investigate the 430-gene ATC signature 
identified by the interspecies analysis, we used Gene Set 
Enrichment Analysis (GSEA) to query the Molecular 
Signatures Database (MSigDB), a large collection of 
curated gene sets [26]. One hundred-nineteen gene sets 
were enriched in both mouse and human ATCs with an 
FDR of less than 10%. This included sets of genes up- and 
down-regulated in anaplastic thyroid carcinoma compared 
to normal thyroid tissue [27] as well as three independent 
sets for mitosis-related genes (Figure 6C).
We next used real time PCR to validate a subset of 
the deregulated genes (marked with an asterisk in Table 
2) using an independent set of tissues from control, 
single mutant, and progressively older double mutant 
mice,  and  histology-confirmed  ATCs.  Dramatic  over-
expression of the top three genes (ranked based on 
Figure 8: Mouse ATCs undergo a glycolytic switch (Warburg effect). (A) Coronal section (transverse in the inset) of representative 
18FDG PET scans of 8-month old control and compound mutant mice, showing high 18FDG accumulation in the thyroid tumor. (B) H&E and 
immunohistochemical detection of Hexokinase II and Pyruvate kinase M2 in the anaplastic component of a representative mouse tumor. 
The line demarcates the boundary between well-differentiated and anaplastic component. (C) Western blotting showing the increased 
expression of Hif1α, Hexokinase II and Pyruvate kinase M2 in four mouse ATCs (T1-T4). (D) Real-time PCR analysis of the expression 
of Hexokinase II, Pyruvate kinase M2, and Lactate dehydrogenase A in five mouse ATCs (T1-T5). (E) Lactate content of four wild type 
thyroids and five ATCs (T1-T5), showing consistent increase in neoplastic glands.Oncotarget 2011; 2:  1109 - 1126 1119 www.impactjournals.com/oncotarget
expression levels in mouse samples), i.e. Timp1, Steap1, 
and  Itga5,  was  confirmed  in  mouse  ATCs  compared 
to wild type controls, single mutants, and aging double 
mutants (Figure 7). The expression of Timp1, an inhibitor 
of matrix metalloproteinases that promotes mitogenesis 
and angiogenesis, and previously found up-regulated in 
thyroid cancer [28] and of Steap1, a cell surface protein 
found over-expressed in various cancers [29] was 
already increased (although at a lower level) in Ptenthyr-/- 
mice, suggesting a direct role of PI3K signaling in their 
regulation. Conversely, Itga5 expression was increased 
only in ATCs, indicating that integrin α5 may play an active 
role in the establishment and maintenance of epithelial-to-
mesenchymal transition [30]. We also validated the over-
expression of Racgap1, Prc1, and Tpx2, which belong to 
the large group of genes involved in the control of mitosis 
[31-33]. Validation of the down-regulation of several 
thyroid differentiation markers is shown in Figure 2. In 
addition, we validated the striking repression of Ppargc1a, 
the gene encoding for the transcriptional coactivator 
PGC1-α, which integrates mitochondrial biogenesis and 
energy production with various cellular functions [34].
Mouse ATCs exhibit a glycolytic switch
Many tumors are characterized by a shift from 
an oxidative to a glycolytic bioenergetic pathway, a 
phenomenon known as the Warburg effect [35]. Human 
ATCs commonly display intense glucose uptake on 
18F-FDG PET imaging, indicating that this tumor type has 
a strong glycolytic phenotype [36].
The down-regulation of Ppargc1a prompted us 
to test whether the ATCs developing in [Pten, p53]thyr-/- 
mice reflect this metabolic shift. We performed 18F-FDG 
PET imaging on sex- and age-matched control and ATC-
bearing mice (8-month old), and found that tumor-bearing 
[Pten, p53]thyr-/- mice avidly uptake radiolabeled glucose 
Figure 9: Both mouse and human ATC cell lines are highly sensitive to glycolytic inhibitors. (A) Top panel: dose-
response curves showing the effect of 2-deoxyglucose (2-DG) on the viability of two mouse ATC cell lines. Middle panel: dose-response 
curves showing the. Bottom panel: isobolograms showing strong synergy between the two compounds. (B) Top panel: dose-response 
curves showing the cooperative effect of a 2-DG/Doxorubicin combination on the viability of two human ATC cell lines. Middle panel: 
isobolograms showing strong synergy between the two compounds. (C) Isobolograms showing strong synergy between doxorubicin and 
another glycolytic inhibitor, 3-bromopyruvate (3-BP).Oncotarget 2011; 2:  1109 - 1126 1120 www.impactjournals.com/oncotarget
(Figure 8A). Furthermore, immunohistochemical, western 
blotting, and real time PCR approaches revealed that 
ATCs developing in [Pten, p53]thyr-/- mice consistently up-
regulate Hif1α, Hexokinase 2, and Pyruvate Kinase M2, 
all of which have been shown to be directly responsible 
for the establishment of the Warburg effect (Figure 
8B-D). Although Ldha, the gene encoding Lactate 
Dehydrogenase A, was not consistently up-regulated 
in mouse ATCs, we found that lactate content of every 
tumor tested was dramatically increased (up to four-fold) 
compared to control thyroids, further demonstrating the 
highly glycolytic nature of these tumors (Figure 8E).
Mouse and human ATC cell lines are sensitive to 
glycolytic inhibitors
Based on these results, we tested whether the 
glycolytic inhibitor 2-deoxyglucose (2-DG), a glucose 
analogue which is phosphorylated by hexokinase but 
cannot be further metabolized in the glycolytic process 
[37], would affect the growth and survival of two cell 
lines we established from ATCs developed by [Pten, p53]
thyr-/- mice. Both cell lines were efficiently inhibited by 
2-DG, showing dose-dependent growth suppression at 
48h with an ED50 (0.3 mM for T1860 and 1.8 mM for 
T1903) remarkably lower than previously reported (6.7-
8.1 mM) for prostate and breast cancer cell lines [37] 
(Figure 9A, top panels), suggesting that ATC cells might 
be especially sensitive to glycolysis inhibition. However, 
glycolytic inhibitors as single agents have shown limited 
efficacy in vivo [38], while their combination with standard 
chemotherapy has shown, in some instances, a promising 
synergistic effect [38, 39]. Thus we tested whether 2-DG 
could enhance the cytotoxic effect of doxorubicin, a 
standard, although poorly effective, treatment for ATC. 
We compared the single agent dose-response curves of 
the two aforementioned mouse ATC cell lines to the curve 
obtained using the two drugs combined at a fixed ratio 
based on the most effective single dose concentration for 
each drug. The combination treatment was more effective 
than each single agent over a wide range of concentrations 
(Figure 9A, middle panels). In order to establish whether 
the combined effects of 2-DG and doxorubicin were 
synergistic rather than additive, we calculated the 
combination index (CI) according to the well-established 
Chou and Talalay median effect method [40]. Figure 
9A (bottom panel) shows the isobolograms for the drug 
combinations in the two cell lines, and the calculated CIs 
for the ED50. Strong synergistic effects (CI<1) resulted 
from the combination of 2-DG and doxorubicin.
Next, we extended these findings to two human ATC 
cell lines, CAL-62 and C643, characterized by different 
driver mutations compared with our mouse model. CAL-
62 harbors a G12R KRAS mutation, while C643 harbors a 
G13R HRAS mutation [41]. In addition, p53 is inactivated 
in both cell lines, consistent with most ATCs [42].
Both human ATC cell lines responded to 2-DG in 
a manner similar to the mouse cells, with an ED50 (0.48 
mM for CAL-62, 1.19 mM for C643) again lower than 
previously reported for other tumor types (Figure 9B, top 
panels). Doxorubicin alone was more effective in CAL-
62 than in C643. When combined in a fixed ratio, the 
two drugs displayed a striking increase in efficacy at all 
concentrations tested, and the CI calculation confirmed 
the strongly synergic nature of this interaction (Figure 9B, 
bottom panels).
To conclusively demonstrate that inhibition of 
glycolysis can effectively synergize with standard 
chemotherapy in ATC, we used a second glycolysis 
inhibitor, 3-bromopyruvate (3-BP), an alkylating agent 
that inhibits hexokinase and GAPDH [43]. Since 3-BP has 
a Ki for glycolysis inhibition of 2.4 mM, while the one 
for DG is 15.5 mM, 3-BP appears to be a more efficient 
glycolysis inhibitor than 2-DG [44]. When combined with 
doxorubicin, 3-BP showed a strong synergistic effect, 
with a CI of 0.3 (Figure 9C).
Taken together, these data strongly suggest that 
anaplastic thyroid carcinomas are highly sensitive to 
glycolysis inhibitors, especially in combination with 
cytotoxic chemotherapy, independent of the nature 
of the driver mutation originally responsible for the 
transformation process.
DISCUSSION
The prevalence of thyroid cancer is increasing 
worldwide, and this is due only in part to improved 
and earlier detection [45]. Although less than 5% of the 
48,020 new thyroid cancer cases (+7.5% compared to 
2010) estimated for 2011 in the United States [46] will 
be diagnosed as anaplastic tumors, the latters will account 
for the majority of the 1,740 estimated annual deaths. The 
dismal  prognosis  associated  with  these  tumors  reflects 
their intrinsic resistance to any therapeutic approach, 
including surgery, radiation, chemotherapy, and targeted 
therapy [6]. The genomic instability and karyotypic 
complexity that characterize ATCs [12] are likely major 
determinants of therapy resistance, since they result in the 
simultaneous activation of multiple oncogenic pathways, 
and thus in the establishment of a redundant network 
offering multiple escape and survival routes. All our 
current knowledge on the pathogenetic mechanisms of 
ATC is based on the analysis of patient material and on 
the use of cell lines and xenograft models. It is thus clear 
that an in vivo, immunocompetent, and clinically relevant 
model of ATC would be a critical tool to better understand 
the mechanisms associated with ATC development, and to 
identify novel, more effective therapeutic targets.
Most ATCs harbor mutations that activate one of two 
pathways that act as drivers of the transformation process: Oncotarget 2011; 2:  1109 - 1126 1121 www.impactjournals.com/oncotarget
the RAS/BRAF/MAPK cascade, and the PI3K/PTEN/
AKT cascade [47]. These mutations are usually already 
present in the well-differentiated tumor component from 
which most ATCs develop [3, 4]. In addition, most ATCs 
share inactivating mutations of p53, which are likely to 
determine, in combination with the driver mutations, the 
anaplastic features of these tumors [48].
Building upon these patient-derived genetic data, 
we  have  generated  the  first  mouse  model  of  ATC  by 
combining, in the mouse thyroid follicular cells, p53 loss 
with constitutive PI3K activation, via deletion of the Pten 
tumor suppressor. 
The most clinically relevant feature of this model is the 
remarkable similarity of its morphological and molecular 
features to human ATCs, including those tumors that do 
not display PI3K activation. [Pten, p53]thyr-/- anaplastic 
tumors derive from pre-existing follicular carcinomas, 
and exhibit cellular pleomorphism, aneuploidy, genomic 
instability, and epithelial-to-mesenchymal transition. This 
latter feature is of particular interest, since recent data in 
the breast and other tissues suggest that EMT is linked to 
the generation of a cancer-initiating cell (or cancer stem 
cell) population [49, 50], endowed with an intrinsic drug 
resistance phenotype [51]. Ongoing studies in this model 
will shed more light on the signals and mechanisms that 
initiate and maintain this phenotype.
The expression of all the classical thyroid-specific 
markers, including that of the sodium-iodide symporter 
(NIS), is lost as a consequence of the de-differentiation 
process. Thus this model provides us with a novel in 
vivo tool to explore the mechanisms leading to NIS 
suppression, and to attempt to pharmacologically restore 
radioiodine sensitivity, as recently described in a model of 
papillary and poorly differentiated BRAFV600E-dependent 
thyroid carcinoma [52].
Another important and clinically relevant feature 
of our model, underlining its high similarity to human 
tumors, is the absence of the dramatic TSH increase typical 
of all current mouse models of advanced thyroid cancer, 
a phenotype that is never seen in human patients [15, 18, 
52]. The possible confounding effects of high TSH levels 
during the transformation process are underlined by the 
absence of neoplastic transformation when these models 
are crossed to Tshr-/- mice [17, 53]. 
Despite the simultaneous loss of Pten and p53, it still 
takes at least 6 months for these mice to develop frank 
carcinomas, which might suggest the need for additional 
genetic alterations to accumulate. Our data exclude the 
presence of mutations in the hotspots of known ATC-
related genes (Braf, H-, N-, and Kras), and indicate that 
a thorough, genome-wide approach to identify possible 
additional cooperating events is warranted.
A noteworthy feature, with important clinical 
implications, is that although ATCs are aneuploid and 
genomically instable, and thus resistant to single agent 
approaches, still they are somewhat addicted to their 
original driver mutation. In fact, a well characterized 
AKT inhibitor, MK-2206, was much more effective on 
cell lines derived from murine [Pten, p53]thyr-/- anaplastic 
tumors than on human cell lines harboring RAS mutations. 
Although this notion will need additional in-depth 
validation, it might represent a valid rationale for the use 
of driver pathway-targeted inhibitors in combination with 
cytotoxic drugs.
Further support to the clinical relevance of this 
model comes from the analysis of its molecular features. 
Expression  profiling  of  control,  single,  and  double 
mutant thyroid glands, compared with follicular and 
anaplastic tumors developed by Ptenthyr-/- and [Pten, p53]
thyr-/- mice respectively, revealed a substantial similarity 
between  Ptenthyr-/- and [Pten, p53]thyr-/- hyperplasias 
and  Ptenthyr-/-  follicular carcinomas, emphasizing the 
driver role of PI3K activation in the establishment of 
neoplastic transformation. Strikingly, ATC profiles were 
significantly different from any other sample, including 
younger [Pten, p53]thyr-/- compound mutants, underlining 
the existence of a dramatic biological switch associated 
with the establishment of anaplasia and EMT. Molecular 
characterization of this switch will undoubtedly yield 
much-needed clues on potential therapeutic targets along 
the pathways involved. While the biological features 
of ATCs predicted an enrichment in genes involved in 
pathways related to EMT, invasion, and metastasis, it is 
interesting that we also found significant alterations in 
groups of genes associated with metabolic pathways, such 
as Propanoate metabolism, Urea cycle, and Arginine and 
proline metabolism, that have been recently associated 
with a neoplastic state [54]. 
Analysis of the overlap between genes significantly 
deregulated in our mouse model and those deregulated 
in the only two Affymetrix-based, publicly available, 
datasets containing human ATCs [24, 25] has allowed us 
to define a set of 430 genes consistently and significantly 
deregulated in both mouse and human ATCs. Strikingly, 
this “ATC signature” is highly enriched in genes encoding 
proteins involved in the control of mitosis, and shows 
a considerable overlap with the “cell proliferation and 
chromosomal instability signature” reported by Salvatore 
et al. using a different platform [12]. The availability 
of novel, specific inhibitors of key mitotic kinases such 
as Aurora A [55] and Plk1 [56] emphasizes the clinical 
relevance of this finding, and, together with preliminary 
reports showing efficacy of Plk1 inhibition in ATC cell 
lines [57], warrants further studies in ATC models using 
these compounds alone or, more likely, in combination 
with other relevant drugs.
Finally, we have provided evidence that, similar to 
human ATCs, [Pten, p53]thyr-/- tumors are highly glycolytic 
and very sensitive to two compounds, 2-DG and 3-BP, 
targeting different steps of glycolysis. Despite a growing 
literature  supporting  the  efficacy  of  anti-glycolytic 
compounds in cancer cell lines [37, 39, 58] as well as in Oncotarget 2011; 2:  1109 - 1126 1122 www.impactjournals.com/oncotarget
xenograft models [38, 44], their clinical development as 
single agents has been slowed down by toxicity-related 
issues associated with prolonged administration of high 
concentrations of these drugs. However, promising results 
have been obtained in clinical trials using 2-DG as a 
radiosensitizer  [59].  More  specific  inhibitors,  with  the 
goal of widening their therapeutic window, are currently 
under development [60]. Our data support the notion that 
glycolysis inhibitors not only decrease proliferation and 
survival of ATC cells as single agents at a relatively low 
concentration, but also significantly increase the efficacy 
of a cytotoxic drug, doxorubicin, already in clinical use 
for ATC. The rationale for this combination is twofold: i) 
DNA damage caused by doxorubicin cannot be effectively 
repaired when the cell’s ATP levels are reduced upon 
glycolytic inhibition; ii) reduced ATP will decrease the 
efficacy of the ATP-dependent pumps responsible for the 
efflux of doxorubicin from the cells. Thus, our proof-of-
principle data provide a strong rationale to develop and 
test additional combinations of novel glycolytic inhibitors 
and clinically relevant chemotherapeutic drugs in sensitive 
tumor types, such as ATC, for which current therapeutic 
approaches invariably fail.
METHODS
Animals
The  PtenL/L and TPO-Cre strains have been 
described [22]. All strains were backcrossed in the 129Sv 
background for at least eight generations, and littermates 
were used as controls. 
Hormone measurements
Blood was collected by cardiac puncture. Serum 
thyroid-stimulating hormone (TSH) was measured using 
a sensitive, heterologous, disequilibrium double-antibody 
precipitation RIA [61], and results were expressed in mU/
liter. All samples were individually analyzed for each 
mouse. Total T4 concentrations were measured by a solid-
phase RIA (Coat-a-Count; Diagnostic Products Corp., Los 
Angeles, CA) adapted for mice. Values of the respective 
limits of assays sensitivities were assigned to samples 
with undetectable TSH and T4 concentration.
Immunohistochemistry
6 µm sections were subjected to antigen retrieval, 
incubated with pERK1/2 (Thr202/Tyr204), pAKT 
(Ser473), pSmad2 (Ser465/467), Vimentin, e-Cadherin, 
HK2, and PKM2 antibodies (Cell Signaling, Danvers, 
MA) and counterstained with hematoxylin. 
Establishment and maintenance of cell lines
Primary thyroid tumors were minced and resuspended 
in Ham’s F12/10% FBS with 100 U/ml type I collagenase 
(Sigma, St. Louis, MO) and 1 U/ml dispase (Roche, 
Indianapolis, IN). Enzymatic digestion was carried out 
for 90 min at 37°C. After digestion, cells were seeded in 
Ham’s F12 containing 40% Nu-Serum IV (Collaborative 
Biomedical, Bedford, MA), gly-his-lys (10ng/ml, Sigma), 
and somatostatin (10ng/ml, Sigma) and allowed to spread 
and  reach  confluence  before  being  passaged. After  the 
fourth passage, tumor cells were adapted to grow in 
DMEM/10%FBS.
Mutation detection
Genomic DNA was isolated from cell lines 
established from primary tumors and subjected to PCR 
to amplify fragments suitable for sequencing [62]. PCR 
products were gel purified and sequenced from both ends.
Metaphase preparation and chromosome analysis
For chromosome preparation, primary cells at 
passage p1-p3 were plated in a 35mm Petri dish and 
incubated with Colcemid (Sigma Aldrich, St. Louis, 
MO) at a concentration of 10 ng/ml over night or for 
3hrs at 100 ng/ml. Chromosomes were extracted with 
standard hypotonic treatment (0.075 M KCl), dropped on 
microscope slides and mounted with antifade containing 
DAPI (Invitrogen, Carlsbad, CA). Slides were imaged 
on a Zeiss Axiovert 200 Microscope using a DAPI filter 
(Chroma  Technologies,  Bellows  Falls,  VT).  Ten  fields 
were selected randomly and 15 to 30 cells for each 
tumor line were subjected to chromosome count and 
visually inspected for the presence of gross chromosome 
abnormalities and chromosome fragments. 
Western blot analysis
Thyroids and cells were homogenized on ice in RIPA 
buffer supplemented with Complete protease inhibitor 
tablet (Roche Diagnostics, Indianapolis, IN). Western 
blot analysis was carried out on 20-40 µg proteins using 
phospho-antibodies from Cell Signaling (Danvers, MA) 
and a β-actin antibody from Sigma-Aldrich.
Drug treatments
Pharmacological inhibitors of AKT (MK-2206, 
Selleck Chemicals), and MEK1/2 (U0126, Cell Signaling) 
were added 24h after plating, in sextuplicate. After 72h, Oncotarget 2011; 2:  1109 - 1126 1123 www.impactjournals.com/oncotarget
viability was assessed using the Wst-1 assay (Takara) and 
IC50s were determined using Prism software.
Real time PCR
Total RNA was extracted with Trizol and reverse 
transcribed using the Thermoscript kit (Invitrogen). qRT-
PCR was performed on a StepOne Plus apparatus using 
the Absolute Blue qPCR Rox Mix (Thermo Scientific, 
Waltham, MA) and TaqMan expression assays (Applied 
Biosystems, Carlsbad, CA). Each sample was run in 
triplicate and Ipo8 was used to control for input RNA. Data 
analysis was based on the Ct method, and experiments 
were repeated at least three times using at least two 
independent organ pools (at least five mice/pool). 
Expression profiling
Three pools of three to five mice, and five individual, 
flash-frozen, histologically verified tumor samples of each 
histotype, were randomly selected from each of the six 
different groups (control, Ptenthyr-/-, p53thyr-/-, [Pten, p53]thyr-
/-, follicular carcinomas, anaplastic carcinomas). Tumor 
fragments and thyroid glands were subjected to total RNA 
isolation using TRIzol Reagent (Invitrogen) followed by 
further purification with the RNAeasy Kit (Qiagen). Total 
RNA quality was verified using the Agilent Bioanalyzer 
2100. Microarray hybridization was performed at the 
Albert Einstein Genomics Facility using Affymetrix 
Mouse Gene 1.0 arrays. Normalization and background 
subtraction were performed with RMA, using the “oligo” 
package of Bioconductor. Gene selection was performed 
using the “limma” package. Raw p values were corrected 
for multiple testing using a “false discovery rate” < 0.05. 
Microarray data were deposited in GEO (accession no. 
GSE30427).
Canonical Pathway Analysis
Canonical pathways analysis identified the pathways 
from the Ingenuity Pathways Analysis library of canonical 
pathways  that  were  most  significant  to  the  data  set. 
Molecules from the data set that met the ±2-fold cutoff 
with a FDR<0.05 and were associated with a canonical 
pathway in Ingenuity’s Knowledge Base were considered 
for the analysis. The significance of the association between 
the data set and the canonical pathway was measured in 2 
ways: 1) A ratio of the number of molecules from the data 
set that map to the pathway divided by the total number of 
molecules that map to the canonical pathway. 2) Fisher’s 
exact test was used to calculate a p-value determining the 
probability that the association between the genes in the 
dataset and the canonical pathway is explained by chance 
alone.
Interspecies analysis
Two human datasets were obtained from GEO 
(E-GEOD-27155: 4 normal vs. 4 ATC) and EBI 
(E-MEXP-2442: 2 normal vs. 4 ATC). The mouse 
dataset (see above) contained six independent wild type 
pools and 5 individual ATCs. .CEL files were processed 
and normalized using the RMA function and the “affy” 
and “oligo” packages of Bioconductor. Data for each 
experiment were normalized separately, due to the different 
Affymetrix platforms used in the three experiments. Gene 
selection for each experiment was done using the “limma” 
package. Raw p values were corrected for multiple testing 
using a “false discovery rate” <0.1. Top tables were 
generated for all probe-sets for each experiment. Human-
mouse homology mapping file were obtained from the 
MGI database (ftp.informatics.jax.org/pub/reports/HMD 
HGNC Accession.rpt) and 11,508 genes common to all 
three datasets were selected. 
Lactate assay
Lactate levels were assayed using a commercially 
available kit (Biovision, Mountain View, CA). Lactate 
levels were normalized to the amount of DNA extracted 
from each tissue fragment.
[18F]Fluorodeoxyglucose positron emission 
tomography imaging
Wild type and [Pten,  p53]thyr-/- mice were 
fasted overnight before a tail vein injection of [18F]
fluorodeoxyglucose (300 μCi). One hour after injection, 
mice were subjected to positron emission tomography 
(PET) scanning with the Concorde Microsystems 
R4 microPET Scanner. Animals were imaged while 
anesthetized  through  inhalation  with  isoflurane.  Image 
acquisition was done using the MicroPET Manager with 
the ASPIRO dedicated software.
Chemotherapic treatments
Doxorubicin (Sigma) and glycolytic inhibitors, 
3-Bromopyruvate and 2-Deoxyglucose (Sigma) were 
added 24h after plating, in quadruplicate. After 48hs cell 
viability was assessed using the Wst-1 assay (Roche). 
Preliminary experiments were conducted to ensure that, 
in the conditions used for these assays, this method yields 
the same results as direct cell counting (both trypan blue-
based and automated).Oncotarget 2011; 2:  1109 - 1126 1124 www.impactjournals.com/oncotarget
Analysis of synergy
Doxorubicin was combined with each of the different 
glycolytic inhibitors at a fixed ratio (1:1) of the individual 
IC90 concentrations of each drug. Drug combinations 
were then serially diluted. Statistical analysis of drug 
synergy was evaluated from the results of the Wst-1 assays 
and calculated using the Chou-Talaly method [40] and 
the Calcusyn Software (Biosoft). To determine synergy 
between two drugs, the software uses a median-effect 
method that determines if the drug combination produces 
greater effects together than expected from the summation 
of their individual effects. The combination index (CI) 
values are calculated for the different dose-effect plots 
(for each of the serial dilutions) based on the parameters 
derived from the median-effect plots of the individual 
drugs or drug combinations at the fixed ratios. The CI 
was calculated based on the assumption of mutually 
nonexclusive drug interactions. CI values significantly > 
1 are antagonistic, not significantly different than 1 are 
additive, and values < 1 are synergistic.
Statistical analysis
Experiments were performed at least three times. 
Data were analyzed using the JMP 5.1, Calcusyn, and 
Prism software packages. Differences with P-values <0.05 
were considered statistically significant.
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